GlassScriptPhysician profile
Paul Papajohn
NPI 1992245179
$3,227.87
in general payments reported to CMS, 2019-2025
14 companies · $908 in 2025
The $908 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $47.29 · 2021: $259 · 2022: $987 · 2023: $147 · 2024: $667 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.31 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,265.15 | 2022-2025 | Xpress Loprofile, Xerogel, Scopis Ent |
| Regeneron Healthcare Solutions, INC. | $407.46 | 2020-2025 | Dupixent |
| Aerin Medical INC. | $401.22 | 2024-2025 | |
| Genzyme Corporation | $303.16 | 2021-2025 | |
| Integra Lifesciences Corporation | $191.91 | 2021-2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Intersect Ent, INC. | $184.97 | 2019-2020 | |
| Inspire Medical Systems, INC. | $146.29 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $75.12 | 2022-2025 | Nucala |
| Medtronic, INC. | $71.87 | 2024-2025 | Propel |
| Optinose US, INC. | $50.69 | 2025 | |
| Cochlear Americas | $49.52 | 2019 | |
| Amgen INC. | $34.00 | 2025 | |
| Hikma Pharmaceuticals USA | $29.92 | 2023-2024 | Ryaltris |
| Smith+Nephew, INC. | $16.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Papajohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.